Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
Improving Protein Capture for Transgenic Drug Processing
Author(s)Ian Sellick
One of the greatest challenges facing biopharmaceutical manufacturers has been the primary recovery of recombinant materials from transgenic sources. As an alternative to existing methods, vibrating membrane technology, which is widely used in food and beverage processing, recently has been adapted to biopharmaceutical applications involving transgenic biosolutions.
Advertisement
Articles in this issue
almost 23 years ago
FDA Will Drive Changes for Contract Businessalmost 23 years ago
In the Spotlight--Decemberalmost 23 years ago
Novemember 2003almost 23 years ago
FDA Seeks Risk-Based Inspection Programalmost 23 years ago
Routine Sample Size for a Retest Procedurealmost 23 years ago
November 2003almost 23 years ago
Clearing Regulatory HurdlesAdvertisement
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement